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A B S T R A C T
The lack of understanding of fundamental nano-bio interactions, and diﬃculties in designing particles stable in
complex biological environments are major limitations to their translation into biomedical clinical applications.
Here we present a multi-parametric approach to fully characterize targeted nanoparticles, and emphasizes the
signiﬁcant eﬀect that each detail in the synthetic process can have on downstream in vitro results. Through an
iterative process, particles were designed, synthesized and tested for physico-chemical and bio-interactive
properties which allowed the optimization of nanoparticle functionality. Taken together all interative steps
demonstrate that we have synthesized a multifunctional gold nanoparticles that can detect ERBB2-positive
breast cancer cells while showing stealth-like behavior toward ERBB2-negative cells and excellent physico-
chemical stability.
1. Introduction
Nanotechnology has seen a surge in interest over the past two
decades. This is most evident in the rise in budget allocations to the
National Nanotechnology Initiative (NNI; USA) from $450 million at its
inception in 2001 to approximately $1.5 billion in 2015 (www.nano.
gov), and the European Commission’s distribution of approximately €1
billion in grants from 2014 to 2015 as part of the Horizon 2020 pro-
gram to nanosciences, nanotechnologies, materials and new production
technologies (ec.europa.eu/programmes/horizon2020). In the biome-
dical ﬁeld this coincides with an increasing number of research pub-
lications regarding nanotechnology and nanomedicine [1], excitement
regarding the intellectual property potential of biomedical nano-
particles (NPs) [2], potential beneﬁts of NPs to innovatively treat dif-
ferent pathologies, and approval of several nano-formulations for
clinical use or investigation in clinical trials [3–7]. Despite the sig-
niﬁcant excitement, there has been little translation of NPs into actual
clinically used products relative to the research output [1,8]. This is in
part due to the relative infancy of the ﬁeld, a lack of understanding of
fundamental nano-bio interactions at cellular and systemic levels, and
diﬃculty in manufacturing particle systems stable in complex biolo-
gical environments [9,10]. One aspect of biomedical NP development
that can be neglected is rational particle design, which is in particular
crucial as typically used nano drug carriers are often highly complex
engineered materials [11–13]. In a 2013 editorial, Howard & Peer [11]
called for more comprehensive and robust physicochemical and biolo-
gical characterization, and a recent perspective by Chan and colleagues
lamented the inability of nanomedicine research to signiﬁcantly im-
prove tumor-targeting with NPs [14].
In this proof-of-concept study, we present a conceptual road map for
the rational design and synthesis of targeted multifunctional gold na-
noparticles (AuNPs), which we developed for breast cancer targeting.
Speciﬁcally, we aimed to emphasize the necessity for multiple and
complementary characterization techniques that can inform critical
steps in the particle development process (e.g. particle colloidal stabi-
lity in complex media and targeting eﬃcacy). Fig. 1 outlines the
iterative process undertaken in particle design using a logical decision
tree to break down the NP design into the four smaller branches, i.e. (I)
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multifunctional NP design; (II) physicochemical characterization; (III)
targeting characterization and (IV) NP uptake/association to breast
cancer cells. Each branch involves multiple analytical steps to ensure
the proper material characterization and in vitro validation in the de-
sign and implementation of targeted AuNPs. Such a road map aims to
provide a template during the rational design of particles for biomedical
applications.
Following the approach presented here, we demonstrate the beneﬁt
of applying an integrated analytical approach utilizing iterative feed-
back during synthesis in order to eﬃciently achieve engineered AuNP
with the desired properties with respect to the intended application.
2. Results and discussion
Several design parameters were initially decided such as particle
type, polymer coating, ﬂuorophore labeling, and bio-conjugation of a
targeting molecule (Fig. 1, branch I). Particle physicochemical char-
acterization was performed using multiple techniques such as
determining optical properties using UV–vis spectroscopy, particle size
and shape with transmission electron microscopy (TEM), colloidal
stability in relevant biological media using depolarized dynamic light
scattering (DDLS) and UV–vis, and successful bio-conjugation via col-
orimetric assay (i.e. Bradford assay), UV–vis and SDS-PAGE with silver
nitrate (AgNO3) staining (Fig. 1, branch II). This battery of analytical
techniques feeds back the particle design – optimizing polymer coating
density and colloidal stability, reducing protein adsorption on the NP
surface, optimizing antibody surface coverage, and tuning targeting
ligand conjugation eﬃciency. Following these steps and optimizing the
NP carrier during this stringent analytical process, signiﬁcantly im-
proved targeting eﬃciency of breast cancer cells (as a targeting model)
as shown by ﬂuorescence-activated ﬂow cytometry, enzyme-linked
immunosorbent assay (ELISA), and DDLS (Fig. 1, branch III). This
approach also yielded crucial information vis-à-vis targeting molecule
orientation, optimal targeting molecule density, and potential inter-
ferences/interactions between ﬂuorophores and targeting molecule ef-
ﬁciency. The latter was then validated using a combination of
Fig. 1. Decision tree for the design of multi-
functional NPs via an integrated approach. In this
iterative process, multiple analytical methods
(grouped in the decision tree with roman nu-
merals) are used throughout each step of the
process to optimize particle design and im-
plementation. The multiple methods are orga-
nized in four branches: (I) multifunctional NP
design; (II) physicochemical characterization;
(III) targeting characterization and (IV) NP
uptake/association to breast cancer cells. Here
we have focused on the parameter that can
directly aﬀect the NP design; however, we
should keep in mind that the selection of the
cell line/biological factors plays a vital role in
this entire diagram. Acronyms in the scheme:
PEG: Polyethyleneglycol; DDLS: Depolarized dy-
namic light scattering; TEM: Transmission elec-
tron microscopy; ERBB2: erb-b2 receptor tyrosine
kinase 2; ELISA: Enzyme-Linked ImmunoSorbent
Assay. Here, the case of targeted AuNPs is used
as example of how to raise decision making.
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inductively coupled plasma-optical emission spectrometry (ICP-OES),
ﬂow cytometry, dark ﬁeld hyperspectral imaging (DF-HIS) and laser
scanning confocal microscopy (LSM) (Fig. 1, branch IV).
2.1. Nanoparticle physico-chemical properties and colloidal stability (inter-
connected branches I and II)
We selected AuNPs as a model particle platform to optimize the
design of a breast cancer-targeting NP. AuNPs were chosen due to their
excellent biocompatibility, ease of synthesis, relatively facile surface
functionalization through S-Au bonds, and the associated straightfor-
ward analytics. AuNPs with a primary diameter of 50 nm were selected
because they oﬀered a convenient surface area to tune the number of
antibodies (Ab) per NP, allowing us to study the possible role of surface
coverage on the targeting eﬃciency of the nanocarrier. The size and
shape of the AuNPs were studied by TEM and UV–vis (Fig. 2). TEM
results conﬁrmed the size (51 ± 7 nm) and spherical shape of the
AuNPs. These AuNPs displayed a localized surface plasmon resonance
(LSPR) band centered at 527 nm (Figs. 2 and S1) which corresponds to
NPs with a diameter of 46 nm [15]. AuNPs were functionalized with
either heterobifunctional carboxyl-PEG-thiol (COOH-PEG-SH) or with a
mixture of COOH-PEG-SH and ﬂuorescently labeled Alexa Fluor 488
(AF488)-PEG-SH (reaction scheme in the Fig. S2A). In the ﬁrst ap-
proach thiolated PEG polymer attaches to the gold surface via the
formation of an Au-S bond and allows attachment of biomolecules to
the pendant −COOH group. In the second approach, the mixture of
polymers (COOH-PEG-SH and AF488-PEG-SH) provides an optical
reporter via the AF488 ﬂuorescent dye and a free eCOOH group for
bioconjugation. The PEGylation produced a slight red-shift (5–6 nm)
due to the change in the refractive index from the presence of PEG on
Au surface, thus conﬁrming the coating (Figs. 2 and S1) [16].
A non-trivial aspect of biomedical NPs is their colloidal stability in
complex biological media. Upon transfer to cell culture media, serum,
or blood, particles enter a solution with high ionic strength and are
rapidly coated by biomacromolecules. This can cause a number of
particulate responses such as particle aggregation, loss of surface
coating, or particle dissolution/degradation [10]. Thus, to ensure col-
loidal stability it is necessary to characterize particles in the appropriate
biological media (e.g. cell culture media). The eﬀect of PEG surface
coverage on AuNPs stability was tested in cell culture media (Dul-
becco’s modiﬁed Eagle’s media, DMEM) supplemented with 10% fetal
calf serum (FCS). UV–vis measurements of AuNPs with a grafting
density of 1, 5, 10, 15, and 30 PEG/nm2 in phosphate buﬀered saline
(PBS) and complete DMEM showed stability for all formulations except
1 PEG/nm2 (Fig. S1). Zeta potential measurements provide insight to
this eﬀect; the 5–30 PEG/nm2 maintained the expected negative surface
charge (−12 to −19mV, Table S1) due to the carboxylic (eCOO−)
end-group of the PEG chain, however 1 PEG/nm2 was close to neutral
(−5 ± 6mV). This decrease in the zeta potential may be due to the
negatively charged eCOO− end group possibly partly embedded in the
voids of the PEG layer on the surface [17].
DDLS and zeta potential conﬁrmed the presence of the PEG layer
around AuNPs. The results shown in Table 1 reveal that unconjugated
PEGylated AuNPs presented higher hydrodynamic radii than the as-
Fig. 2. UV–vis spectra of AuNPs in PBS with
varying degrees of functionalization. Bare
50 nm AuNPs are shown (black lines), as well
as PEGylated AuNPs (red lines), and PEGylated
AuNPs functionalized with TZB (blue lines).
Diﬀerent panels show PEGylated AuNPs func-
tionalized with 100×TZB per particle (Au-
PEG-100TZB) (A), 100×TZB per particle with
AF488 labeled on the TZB molecule (Au-PEG-
100TZBAF488) (B), PEGylated AuNPs with
5×TZB per particle with the AF488 dye la-
beled on the PEG chain (Au-PEGAF488-5TZB)
end (C), and PEGylated AuNP with 100×TZB
per particle with the AF488 dye labeled on the
PEG chain end (Au-PEGAF488-100TZB).
UV–vis spectra were normalized by the ex-
tinction maximum. Insert TEM image shows
bare 50 nm AuNP with the scale bar re-
presenting 200 nm (For interpretation of the
references to color in this ﬁgure legend, the
reader is referred to the web version of this
article).
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synthesized AuNPs: 59.5 nm for Au-PEG and 65.6 nm for Au-PEFAF488
vs. 27.5 nm for non-functionalized AuNPs. The surface grafted PEG
chains can acquire either a “brush” or “mushroom” conformation. The
latter mainly occurs when distance between the attachment points of
PEG to the surface is larger than the Flory radius (RF), while the brush
conformation is observed when this distance is smaller than RF [18].
Both PEGylated AuNPs presented a referred distance and grafting
coverage of 0.47 nm and 0.54 PEG/nm2 (Au-PEG) and 0.44 nm and
0.64 PEG/nm2 (Au-PEGAF488) respectively, as obtained by a method
previously described [17]. This indicated that the PEG layers deposited
on the AuNPs possessed a brush-like conformation because the RF for
5000 Da PEG is 4.9 nm. In contrast, no considerable hydrodynamic size
changes were observed upon TZB coupling to any of the PEGylated
AuNPs (Table 1), which could be attributed to the compression of
neighboring PEG molecules [19].
We qualitatively evaluated the serum protein adsorption levels from
the changes in the hydrodynamic radii estimated by DDLS measure-
ments of all AuNPs in PBS buﬀer and complete DMEM. This method
oﬀers scattering information originating exclusively from the NPs on an
essentially zero-background [20], which is not achievable using con-
ventional DLS. As shown in Table S1, the size of carboxyl-terminated
PEGylated AuNPs remains unchanged under all conditions, suggesting
that these particles are not aﬀected by the biomolecules present and
remain colloidally stable. This ﬁnding is in agreement with UV–vis
spectra data in Fig. S1 showing the absence of signiﬁcant size changes
except in the case of the 1 PEG molecule/nm2 grafting density, where a
small shoulder at 600 nm appears due to a slight aggregation. With
these results, we conﬁrmed that the PEG layer acts as an anti-biofouling
agent and that all formulations were colloidally stable in the respective
environment. In addition, we examined the possibility of PEG layer
displacement from the Au surface by measuring the ﬂuorescence in-
tensity of Au-PEGAF488 in PBS vs. ﬂuorescence intensity in supple-
mented DMEM and FACS buﬀer after 4 h dialysis (see details in the SI).
Fig. S3 shows very low ﬂuorescence decay, which proves that no sig-
niﬁcant PEG displacement is produced.
Thus, the colloidal stability measurements (branch II Fig. 1) have
emphasized two important points. Firstly, colloidal stability can be an
overlooked aspect of particle design and synthesis. For example, stan-
dard DLS to evaluate NP colloidal stability in complex media is in-
suﬃcient because “zero-background” cannot be achieved in protein-
rich media, and therefore require specialized techniques (i.e. DDLS) or
advanced expertise to avoid misinterpretation of data. The main reason
is that the magnitude of the speciﬁc measurement property (i.e. light
scattering) of the biomolecules can be of the same order as the NPs,
which generates a biased analysis [20]. Particle stability in puriﬁed
H2O does not entail particle stability in more complex solutions.
Therefore, multiple robust and sensitive characterization methods are a
necessity to glean a complete understanding of NP colloidal stability in
complex media. Secondly, NP design parameters such as particle sta-
bilizing molecule surface coverage and “long term” particle stability
need to be considered. Having optimized these factors, we could pro-
gress to determining cellular targeting eﬃcacy.
2.2. Breast cancer cells as a relevant model to evaluate nanoparticle
targeting eﬃciency (important factor for branches III and IV)
Tumor-targeted AuNPs are considered a promising platform for NP-
based diagnostics and therapy. Tumor cells often diﬀerentially express
cell surface molecules (receptors) compared to normal cells. Such re-
ceptors can be exploited for targeting, diagnostic and therapy using
proteins (e.g. transferrin) [21], small molecules [22], aptamers [23,24],
peptides [25,26], or monoclonal antibodies (mAbs) [27,28]. However,
the use of targeting ligands for particle-mediated diagnostics or therapy
is a complicated matter. Generally, particles are envisioned for systemic
administration into the bloodstream, and once there a targeted particle
must localize and be retained at the site of action. However, particles in
circulation will naturally be cleared by the body, must bind to target
sites in dynamic and competitive environments, may exhibit oﬀ-target
binding, and most are aimed at heterogeneous cell populations (and
therefore show variable eﬃcacy) [29]. Moreover, there can be shielding
of targeting ligands via speciﬁc or non-speciﬁc protein adsorption (i.e.
formation of a protein corona) on the particle surface [30]. In this
context, particle targeting must rely on speciﬁc optimization of the
targeting ligand attachment to the particle, and in-depth characteriza-
tion of the targeting eﬃcacy.
In order to evaluate the targeting eﬃciency of our multifunctional
AuNPs platform we used three human breast cancer cell lines expres-
sing diﬀerent levels of the receptor tyrosine-protein kinase erbB-2
(ERBB2), also known as human epidermal growth factor 2 (HER2).
ERBB2 is overexpressed in many cancers, including a subtype of breast
cancer, compared to normal cells [31]. The anti-ERBB2 antibody
Trastuzumab (TZB, humanized IgG1) is therapeutically used in patients
with ERBB2-positive tumors to block ERBB2 signaling and has been
used experimentally for tumor targeting purposes [32–34]. Thus, we
selected TZB as a model mAb for targeting ERBB2-positive breast
cancer cells to test the various parameters pertinent to the NP design
process.
We used unlabeled free TZB and a secondary ﬂuorescent Ab in a
FACS analysis to monitor the expression of ERBB2 in three breast
cancer cell lines: BT-474 human breast ductal carcinoma, as well as SK-
BR-3 and MDA-MB-231 human breast adenocarcinomas. Fig. S4 shows
the FACS data and the calculated number of ERBB2 receptors normal-
ized by the cell area of the cells. BT-474 expressed the highest level of
ERBB2, SK-BR-3 slightly less and MDA-MB-231 the least. Based on this
and the previous conﬁrmation of AuNPs colloidal stability, we then set
to develop the ERBB2-targeted AuNPs.
Table 1
Physicochemical properties of the AuNPs sets.
Samples Hydrodynamic
Radiusa (PDb)
[nm]
Zeta
Potentialc
(± SD)
[mV]
AF488/
AuNPd
(± SD)†
Ab/
AuNPe
(± SD)
Au 27.5 (40.0) −15.9 (1.7) – –
Au-PEG 59.5 (71.6)‡ -6.9 (1.6) – –
Au-PEG-
100TZBAF488
53.8 (81.5)‡,§ −15.3 (4.5) 363 (113) 97
(5)*(**)
Au-PEG-100TZB 54.5 (82.8)‡,§ −25.8 (1.5) – 101 (1)*
Au-PEGAF488 65.6 (82.8)‡ −11.0 (4.6) 417 (225) –
Au-PEGAF488-
100TZB
70.5 (104.9)‡,§ −12.0 (3.7) 417 (225) 100 (1)*
Au-PEGAF488-
5TZB
74.7 (106.0)‡,§ −13.5 (2.9) 417 (225) 4 (1)
* and (**) Indicate a signiﬁcant diﬀerence from Au-PEGAF488-5TZB and Au-
PEG-100TZB, respectively, as compared by a one-way ANOVA and Turkey’s
HDS test (p < 0.05).
a Mean hydrodynamic radius was obtained by DDLS at room temperature
and at a scattering angle of 90°. DDLS measurements were carried out in tri-
plicate.
‡ Indicates a signiﬁcant diﬀerence from Au as compared by a one-way
ANOVA and Turkey’s HDS test (p < 0.05).
§ Indicates a signiﬁcant diﬀerence from respective PEGylated AuNPs as
compared by a one-way ANOVA and Turkey’s HDS test (p < 0.05).
b Polydispersity (%).
c Zeta-potential in PBS were measured in 10 runs (mean ± SD).
d Fluorescence was measured on a VICTOR plate reader with the ﬁlter set
560/615.
† No signiﬁcant diﬀerence observed between Au-PEG-100TZBAF488 and the
set of Au-PEGAF488 as compared by a one-way ANOVA and Turkey’s HDS test
(p < 0.05).
e Total protein estimation using Branford assay.
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2.3. Trastuzumab maintains ERBB2 binding eﬃciency following
nanoparticle conjugation (Inter-connected branches I, II and III)
To design ERBB2-targeted AuNPs, we conjugated TZB to the car-
boxylic groups of PEGylated AuNPs through a two-step protocol using a
carbodiimide chemistry (Bioconjugation reaction in the Fig. S2B) [35].
We designed four targeted multifunctional AuNPs: (1) Unlabeled PE-
Gylated AuNPs with a full surface TZB coverage (Au-PEG-100TZB),
used as control. (2) Unlabeled PEGylated AuNPs with a full surface
coverage of TZB directly labeled with AF488 (Au-PEG-100TZBAF488),
used to investigate the ﬂuorophore eﬀect on the TZB binding eﬃciency.
(3) AuNPs with AF488-labeled PEG (Ratio 1:1 PEG:PEGAF488) with
low surface coverage of TZB (Au-PEGAF488-5TZB), used to examine
the eﬀect of TZB surface coverage on the binding eﬃciency. (4) AuNPs
with AF488-labeled PEG (Ratio 1:1 PEG:PEGAF488) with full surface
coverage of TZB (Au-PEGAF488-100TZB), used to test the TZB binding
eﬃciency when the ﬂuorophore is on the PEG. Detailed physicochem-
ical properties of the prepared AuNPs are summarized in Table 1.
To validate the successful conjugation of TZB to the AuNPs, AuNP-
PEG-TZB was analyzed by reducing SDS-PAGE electrophoresis (see
details in SI). AgNO3 gel staining showed bands at 50 and 25 kDa,
conﬁrming the successful conjugation of TZB to the particles (Fig. S5).
To determine the average number of TZB molecules attached to each
AuNPs, we indirectly quantiﬁed non-attached TZB during the bio-
conjugation step using the Bradford assay. We determined Ab con-
jugation was highly eﬃcient (yield> 93%, Table 1). The number of
AF488 molecules per AuNPs in labeled TZB (Fig. S6) and PEGAF488
AuNPs were similar (Table 1), thereby eliminating bias in the com-
parison of receptor binding eﬃciency due to the diﬀerence in the
ﬂuorescence labeling. The zeta potential values demonstrated that the
AuNPs retained their negative surface charge despite of attached TZB.
In addition, we assessed colloidal stability of the multifunctional AuNPs
in DMEM containing 10% FCS and FACS buﬀer (5mM EDTA, 3% FCS in
PBS) by UV–vis spectroscopy. No large shift and broadening of the LSPR
were observed for any of the TZB-conjugated AuNPs, thereby excluding
aggregation (Fig. S7) [36].
As the covalent conjugation of TZB on the AuNP surface could im-
pact the TZB binding eﬃciency to ERBB2 [34], we determined the
AuNP-PEG-TZB binding capacity to recombinant ERBB2 extracellular
domain (ECD) in two assays (Branch III in Fig. 1): ELISA and DDLS
(Fig. 3). To conﬁrm the successful binding of multifunctional AuNPs to
soluble ERBB2-ECD, we analyzed the formation of TZB-AuNPs-ERBB2-
ECD complexes in suspension by monitoring changes in the hydro-
dynamic size using time-resolved DDLS. The results were compared
with Au-PEG particles incubated with ERBB2-ECD. PEGylated AuNPs
showed no aﬃnity for the ERBB2-ECD. The anti-human IgG antibody-
conjugated AuNPs acted as positive control by non-speciﬁcally binding
to ERBB2-ECD. Fig. 3A–C displays the results of 2 h RT kinetic mea-
surements of three diﬀerent TZB:ERBB2-ECD ratios: 1:1, 1:2 and 1:5
with 1× 1010 AuNPs, which corresponds to 1× 1012 TZB molecules.
This incubation time was chosen in accordance with previous FACS and
ICP-OES experiments.
When Au-PEG-100TZB was incubated in ERBB2-ECD in aqueous
solution, a very rapid response occurred. Even within the ﬁrst minute,
time-resolved DDLS was not able to reveal the initial phase of the TZB-
AuNPs:ERBB2-ECD interaction. During time we observed an increase of
hydrodynamic size for TZB-conjugated AuNPs while no changes were
observed for PEG-coated AuNPs. This increase in size is due to the
ERBB2-ECD binding to TZB on AuNP resulting in a greater total hy-
drodynamic radius (Rh). The ΔRh was found to be 8.3 nm for a 1:1 ratio,
13.2 nm for a 1:2 ratio and 24.7 nm for a 1:5 ratio. As TZB is endowed
with two identical antigen-binding sites, it is possible that it binds one
or two ERBB2-ECD depending on its concentration. Troise et al. [37]
reported that TZB can simultaneously bind two receptor molecules at
low concentration, while at high concentration the binding is mainly
monovalent. In our case, the concentration of TZB used was 3.3 nM, for
which the system was most likely in the two-site binding regime.
However, the presence of AuNPs most likely aﬀects the antibody-an-
tigen binding kinetics, given that the binding equilibrium is not reached
in 2 h. Yin et al. [34] reported that the presence of AuNPs has an eﬀect
on binding kinetics of TZB with ERBB2-expressing cells: nanoconjugates
exhibited faster association rate constant than free TZB molecules.
However, the dissociation rate constants were also much faster for
nanoconjugates, resulting in a weaker binding aﬃnity than that of free
TZB. This is likely due to the negative charge of TZB-conjugated AuNPs
that inhibits its accessibility to the negatively charged cell membrane.
ELISA was performed to determine the ability of TZB-conjugated
AuNPs to recognize surface immobilized ERBB2-ECDC (i.e. coated on
wells of a 96-well plate). Fig. 3E shows the same trend that with DDLS
experiments. Taken together, these results indicate that TZB conjugated
to AuNPs retains its aﬃnity for ERBB2-ECD.
2.4. Speciﬁc orientation of Trastuzumab for optimal ERBB2 targeting
(Branch III)
With the chosen conjugation strategy, Abs can be bound to the
AuNP in a number of ways and orientations, some of which can inter-
fere with access to the binding site, possibly resulting in a decreased
activity of the bound Abs. As an example, the activity of a single chain
Ab fragment against human cancer antigen TAG-72 bound at about a
1:1 M ratio to PEG is decreased up to 40% [38]. Even greater reduction
has been observed when multiple PEG chains are conjugated to a single
Ab [39]. A directed Ab conjugation strategy helping correct orientation
of the Ab was reported to favorably aﬀect the accessibility of antigen
binding sites [40–42]. Therefore, TZB conjugation was carried out by
controlling orientation of the Ab on the NP surface through ionic and
covalent interactions [43]. This approach is based on the fact that when
the pH of an Ab solution is lower than the Ab isoelectric point, the
concentration of positive charges (eNH3+ group of Lys residues) in the
Fc region of the Ab is high. As negatively charged PEGylated AuNPs
(COO− group of PEG) preferentially interact with the positively
charged Fc region of TZB this results in amide bond formation in the Fc
region, while leaving the antigen binding sites largely free (Fig. S2B).
We chose two TZB surface coverage densities (i.e. full coverage at 100
TZB per AuNPs and low coverage at 5 TZB per AuNPs) to study the
eﬀect of the ERBB2 binding eﬃciency.
We initially investigated if the ratio of PEG:PEGAF488 inﬂuenced
targeting to BT-474 (high expressing ERBB2, Fig. S4). AuNPs with
PEG:PEGAF488 of 1:100 or 1:1 (with equivalent TZB conjugation) were
tested by FACS (Table S2). To increase sensitivity, a secondary IgG-
AF488 Ab was used. A PEG:PEGAF488 of 1:1 was optimal for BT-474
targeting (Fig. 4A). ERBB2 targeting was further evaluated by com-
paring TZB linked to the AuNPs via the ﬁxed orientation vs. conven-
tional carbodiimide protocol. Results from these experiments showed
better binding when the TZB was conjugated with the ﬁxed orientation
method for both 5×TZB per NP (Fig. 4B) and 100×TZB per NP
(Fig. 4C).
These experiments identiﬁed two important factors to consider
when optimizing targeted NP design. Firstly, the density of ﬂuorophore
can have an important role in the targeting eﬃciency because their
presence can reduce the association of AuNPs-conjugated Abs with their
receptor by increasing steric hindrance [44,45]. The optimization of
ﬂuorophore density is also important to avoid ﬂuorescence decay when
dye molecule aggregates as described previously [46]. Secondly, tar-
geting ligand orientation is also critical to minimizing hindrance of the
Fab binding site not only due to directly covalently modiﬁcation (at-
taching Ab through Fab to the NP), but also to Fab shielding because of
its embedding in the polymer layer [47].
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2.5. Signiﬁcance of detection method on cell-targeting nanoparticle
association (Branch IV)
The speciﬁcity of TZB-conjugated AuNPs for ERBB2-positive breast
cancer cells was investigated using the three aforementioned human
breast cancer cell lines. Diﬀerent targeted AuNP formulations were
incubated with cells for either 2 h or 24 h, and uptake of AuNPs was
determined via ICP-OES and FACS. To verify that there were no adverse
eﬀects on cells following NP exposure, cells were ﬁrst incubated with
AuNPs at 40 μg/mL. No morphological changes in phase contrast
images of living cells (Fig. S8) and excellent viability in the MTT via-
bility assay [48] were observed after 24 h of AuNPs incubation with the
three breast cancer cell lines (Fig. S9).
Cell-speciﬁc binding eﬃciency of targeted multifunctional AuNPs
was tested by incubating various AuNPs for 2 h with the three cell lines
followed by FACS analysis. A secondary AF488-conjugated anti-human
IgG antibody was added to enhance detection [49]. Speciﬁc targeting in
ERBB2 positive BT-474 and SK-BR-3 cells was achieved for the four
TZB-conjugated multifunctional AuNPs at higher MFI values (Fig. 5A
and B). In the case of Au-PEGAF488-100TZB, diﬀerences in MFI be-
tween MDA-MB-231 (low ERBB2 expression), BT-474 and SK-BR-3
(high ERBB2 expression) were statistically non-signiﬁcant (*p < 5;
MDA-MB-231: 2.24 ± 0.84; BT-474: 2.68 ± 0.24 and SK-BR-3:
4.09 ± 1.92). This could be attributed to increased non-speciﬁc en-
docytic uptake, which has been observed when the gold surface is
coated fully with Abs [33,34]. Thus, discrimination between the BT-474
and SK-BR-3 was achieved only with Au-PEG-100TZB (3.30 ± 0.14 for
BT-474 vs 6.12 ± 2.73 for SK-BR-3).
FACS conﬁrmed that none of the non-targeted, PEGylated (no TZB)
AuNPs associated with any of the cancer cell lines (Fig. 5A and B). This
result is consistent with a brush conformation of PEG on the Au surface,
which mitigates protein adsorption and non-speciﬁc endocytosis as
reported for dendritic cells [50]. FACS analysis was complemented by
ICP-OES analysis allowing direct quantiﬁcation of gold associated with
the cells (Fig. 5C and D). A control experiment (Fig. S10) showed that
there was no signiﬁcant absorption of AuNPs onto well plates in the
absence of cells, therefore excluding signals due to AuNPs bound to
plastic. In contrast, all TZB-conjugated AuNPs showed cellular asso-
ciation. All four TZB-conjugated AuNPs showed higher binding eﬃ-
ciency for BT-474 and SK-BR-3 cell lines.
We observed some discrepancies between the cellular binding of
AuNP detected by FACS (Fig. 5A and B) vs. ICP-OES (Fig. 5C and D).
Fig. 5E shows the comparison between FACS and ICP-OES analyses.
This qualitative correlation clearly demonstrates the impact of the
presence of AF488 and TZB surface coverage on AuNPs binding eﬃ-
ciency. The presence of ﬂuorophore on AuNPs did not signiﬁcantly
impact binding to ERBB2, since the values for Au-PEG-100TZBAF488
(AF488 bound to TZB) and Au-PEGAF488-100TZB (AF488 bound to
PEG) did not present any signiﬁcant change compared to control (Au-
PEG-100TZB). However, a decrease in TZB surface coverage not only
had an impact on the NP-cellular association, but also resulted in a
worse correlation between the two techniques. This may be due to the
fact that while in TZB-conjugated AuNP TZB is the dominant factor
driving AuNP-cancer cell association, in the absence of TZB, the
ﬂuorophore passive targeting via nonspeciﬁc cellular uptake pathways
may become more prominent [50]. Therefore, as the number of TZB
molecules at the AuNP surface decreases the presence of “non-shielded
PEG” on the Au surface increases resulting in decreased nonspeciﬁc
Fig. 3. Time-resolved DDLS study started promptly after incubating AuNP-PEG (A), AuNP-PEG-IgG (B), or AuNP-PEG-TZB (C) in presence of soluble ERBB2-ECD at
diﬀerent concentrations in water (ratio of TZB to ERBB2-ECD). The dashed lines correspond to the hydrodynamic size of AuNPs in PBS buﬀer. Hydrodynamic radius
measurements are summarized in the table (D). * Indicates a signiﬁcant diﬀerence from the respective hydrodynamic size in PBS as compared by a one-way ANOVA
and Turkey’s HDS test (p<0.05). (E) ELISA assay performed in the presence (blue) and absence (red) of ERBB2-ECD protein veriﬁed the speciﬁcity of Au-PEG-
100TZB to ERBB2-ECD. As negative control, a well coated with ERBB2-ECD protein was used. The absorbance was normalized with respect to negative control (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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Fig. 4. FACS analysis showing the eﬀect of
PEG:PEGAF488 grafting density, TZB coverage,
and TZB orientation on ERBB2 targeting eﬃ-
ciency. BT-474, due to their high ERBB2 ex-
pression, was used as a model cell line. FACS
sensitivity was increased by tagging TZB with a
secondary AF488-labeled IgG Ab (IgG-AF488).
Minimizing the PEG:PEGAF488 ratio (1:1 ratio,
Persian green peak) was shown to increase
ERBB2 targeting (A). Orienting TZB conjuga-
tion to AuNPs was also shown to improve
ERBB2 targeting eﬃciency for both 5×TZB
per NP (dark green peak) (B) and 100×TZB
per NP (dark green peak) (C). Inset red square
in each FACS graph shows a zooming of spe-
ciﬁc area of the peaks (For interpretation of the
references to color in this ﬁgure legend, the
reader is referred to the web version of this
article).
Fig. 5. Cellular association of AuNPs de-
termined via FACS (A, B) and ICP-OES (C, D)
after exposure for 2 h. The location of the
ﬂuorophore label was tested (i.e. AF488 con-
jugated to the PEG chain end vs. conjugated to
the Fc chain of TZB), as well as the TZB den-
sity. In order to compare the two methods,
normalized AuNPs association by MDA-MB-
231 (upper panel, green), BT-474 (middle
panel, red) and SK-BR-3 (lower panel, blue)
was shown as a function of TZB conjugation
and detection techniques, FACS (triangle) and
ICP-OES (square). For FACS measurements (A,
B), samples were measured in sextuplicate
(light green, red and blue diamonds). The black
spheres indicate the mean values ± SD. Solid
horizontal line indicates the normalized MFI of
untreated cells and dotted horizontal lines in-
dicates the normalized MFI of non-speciﬁc
staining of AF488-labeled secondary antibody.
Krauskal-Wallis and U-Mann-Whitney non-
parametric tests were performed to evaluate
non-statistically signiﬁcant diﬀerences with
untreated cells (* p < 0.05) and non-speciﬁc
staining of secondary antibody (**p < 0.05).
For ICP-OES measurements (C, D) each condi-
tion was measured in triplicate (semi-trans-
parent diamonds). The black spheres and lines indicate the mean values and SD respectively. Split-plot ANOVA with Huynh-Feldt correction for non-sphericity and
Bonferroni’s post hoc test were performed to evaluate non-statistically signiﬁcant diﬀerences with Au-PEG and Au-PEGAF488 (* p < 0.05), respectively (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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uptake. This eﬀect may be relevant for in vivo experiments because
reducing the coverage of Ab on NP will also results in fewer Fc portions
available for binding to Fc receptors expressed in immune cells [51].
Therefore, optimization of Ab surface coverage is important to max-
imize targeting eﬃciency and minimize non-speciﬁc receptor binding
and NP clearance. Furthermore, the diﬀerence observed between FACS
and ICP-OES cell association data, is likely due to the fact that a sec-
ondary labeled antibody was required for FACS analysis. Having fewer
Fc portions available due to the low amount of TZB on AuNP surface
results in a weaker ﬂuorescence enhancement compared to AuNPs with
full surface TZB coverage.
2.6. Targeted imaging (Branch IV)
To further conﬁrm targeting of the breast cancer cells by the four
TZB-conjugated AuNPs, we performed dark ﬁeld optical microscopy
with hyperspectral imaging (DF-HSI). DF-HSI detects light that is
elastically scattered by the metallic NPs. It is a powerful tool for ima-
ging at the single-particle level, making it an alternative imaging
technique for AuNPs [52]. After 24 h incubation about 30% of AuNP
were cell associated, compared to 8% at 2 h (Fig. S11). We therefore
decided to perform DF-HSI analysis at 24 h. Under a dark-ﬁeld micro-
scope, where only scattered light is collected [53], TZB-conjugated
AuNPs could be clearly seen as red/orange dots associated with the
cancer cells while no signiﬁcant diﬀerences in scattering were observed
in the cells incubated with Au-PEG or Au-PEGAF488 compared to cells
alone (Fig. S12). This further conﬁrms that PEGylated AuNPs do not
interact with cells. BT-474 and SK-BR-3 cells exposed to TZB-con-
jugated AuNPs display a more intense scatter than MDA-MD-231 cells,
consistent with higher targeted multifunctional AuNPs binding and in
agreement with the ICP-OES results (Fig. S11). Therefore, speciﬁc
ERBB2 targeting was further conﬁrmed (qualitatively) with DF-HSI.
Confocal laser scanning microscopy was attempted to examine the
localization and distribution of TZB-conjugated AuNPs with higher
precision. A secondary labeled Ab was used to enhance the ﬂuorescent
signal of the TZB (similar to the FACS studies) as it was not possible to
image the ﬂuorophores labeled on the AuNPs directly. This is likely due
to either self-quenching where emitted photons are reabsorbed by other
AF488 ﬂuorophores when AF488 molecules are in close proximity
(which is favored for the nanoscale size of AuNPs) [54] or from the non-
ﬂuorescent complex formation with amino acids (either free moieties or
formed part of protein structure) [55]. BT-474 cells were incubated
with NPs at 40 μg/mL for 24 h or with free TZB. BT-474 cells treated
with Au-PEGAF488-100TZB exhibited similar patterns of membrane
ERBB2 localization as cells incubated with free TZB (Fig. 6). A previous
report showed that ERBB2 receptors undergo endocytosis when bound
to TZB adsorbed AuNPs with a diameter of 40 and 50 nm due to
receptor clustering through binding to multivalent AuNPs-bound TZB
[56]. However, we found no evidence that Au-PEG-TZB or Au-
PEGAF488-TZB enhances ERBB2 internalization. This is consistent with
the lack of toxicity observed for all TZB-conjugated AuNPs (see MTT
assay, Fig. S9), as induction of cell death by TZB involves ERBB2 in-
ternalization [34,54,56]. Fluorescent signal of the anti-TZB secondary
Ab was noticeably weaker for AuNP-PEGAF488-100TZB compared to
free TZB. This is possibly due to steric hindrance as the anti-TZB sec-
ondary Ab binds to the Fc region of TZB, which in the case of AuNPs-
PEGAF488-100TZB, is covalently bound to the PEG.
3. Conclusions
We demonstrated the beneﬁt of applying an integrated analytical
approach utilizing “feedback loops” during the synthesis process in
order to eﬃciently achieve engineered AuNPs. We showed that by using
an appropriate process to break down a complex system (fabrication of
the optimal targeted nanocarrier) into four smaller packages (I. design;
II. physicochemical characterization; III. targeting characterization; IV.
NP uptake/association), we can better steer and more assuredly succeed
in designing a functional NP with the desired properties respective to
the intended application. The outcome of one step may cause a re-
evaluation of previous decisions. On the contrary, a synthetic approach
uncoupled from in-depth analytical considerations may lead to the use
of an inappropriate process or waste resources/time because it is unable
to break down a complex system into the necessary elements to solve it.
As a consequence, the system remains too complex and may fail in
delivering the sought after particle without gaining understating for the
putative reasons.
Following the decision tree, we designed and established multi-
functional AuNPs with requisite characteristics for targeted imaging
purposes: (i) A hydrophilic PEG outer shell leading to colloidal stability
and reduced nonspeciﬁc protein adsorption; (ii) scattering and ﬂuor-
escent properties provided by the unique optical properties of gold and
by the covalent linkage of Alexa Fluor 488 to the PEG, respectively, and
(iii) surface functionalization with biologically active ligands that en-
abled speciﬁc targeting. The AuNPs were surface-functionalized with
PEG as an anti-fouling agent and conjugated with TZB as an ERBB2-
targeting NP system. These targeted nanocarriers showed a strong af-
ﬁnity and high speciﬁcity to ERBB2-positive cells. These experiments
and data show the signiﬁcance of proper material characterization and
in vitro validation in the design and implementation of targeted AuNPs.
4. Experimental Section
All glassware was washed with aqua regia and extensively rinsed
with water prior to use. Milli-Q grade water was used in all
Fig. 6. Laser confocal ﬂuorescence microscopy of BT-474 cells treated for 24 h with free TZB, Au-PEGAF488-100TZB, and an untreated control. TZB binding was
revealed with AF488 labeled secondary IgG antibody (yellow). The nucleus was counterstained with DAPI (cyan). Scale bar is 20 μm. Both free TZB and Au-
PEGAF488-100TZB was localized on cellular membrane. Limited NPs-ERBB2 receptor internalization was observed (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article).
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preparations. All the chemicals were used without further puriﬁcation.
4.1. AuNPs synthesis
Citrate-stabilized AuNPs (20 nm in diameter) were prepared as de-
scribed [57]. Brieﬂy, a vigorously stirred aqueous tetrachloroauric acid
(HAuCl4× 3H2O; 125mL, 0.25mM; Sigma-Aldrich, Buchs, Switzer-
land) solution was brought to a boil followed by rapid addition of 3mL
of 40mM sodium citrate (Sigma-Aldrich). Within 20min the color of
the solution changed to red, indicating the formation of AuNPs.
50 nm AuNPs were synthesized by overgrowth of Au onto the 20 nm
citrate-capped AuNPs (seed dispersion, Fig. S1), as described in Brown
et al. [58]. The growth step was carried out by addition of hydro-
xylamine-hydrochloride (NH2OH∙HCl; 3 mL of 0.2 M; Sigma-Aldrich)
and the 20 nm citrate-capped AuNP dispersion (15mL) to a solution of
HAuCl4 (0.25 mM in 270mL). The resulting AuNPs were washed by
centrifugation (4000 rpm, 20min) and re-dispersed in Milli-Q water.
4.2. AuNPs functionalization with thiolated PEG
Carbodiimide chemistry was used to conjugate the primary amines
of the hetero-bifunctional thiolated PEG (NH2-PEG-SH, MW 5000,
Creative PEG-Works, Winston-Salem, NC, USA) with the activated
carboxyl groups of the Alexa Fluor 488 NHS ester (AF488 NHS; Thermo
Fischer, Reinach, Switzerland), forming an amide functional group as
previously described in Rodriguez-Lorenzo et al. [50]. Brieﬂy, 75mg of
polymer, 300 μL of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
(EDC; Sigma-Aldrich) (2% w/v EDC) in pH 7.4 phosphate buﬀered
saline 1X (PBS; Life Technologies, Thermo Fischer), and 90 μL of Alexa
Fluor® 488 NHS (AF488 NHS; Invitrogen, Thermo Fischer) solution
(2mg/mL in DMF) were mixed on a shaker overnight at room tem-
perature. The conjugated polymer was puriﬁed by dialysis and lyo-
philized for 2 days (stored at −20 °C).
In order to design multifunctional AuNPs, two sets of PEGylated
particles were prepared: unlabeled and labeled PEGylated AuNPs. The
PEGylated AuNPs sets were prepared by adding either COOH-PEG-SH
(Mw 5000, Creative PEG-Works, Winston-Salem, CN, USA) or a mixture
of two hetero-functional thiolated PEG [COOHPEG:AF488PEG] at a
ratio of 1:1, COOH-PEG-SH for attaching an antibody and AF488-PEG-
SH for providing the ﬂuorescence functionality, dropwise to 10mL of
synthesized AuNPs under shaking to reach a ﬁnal PEG concentration of
10 PEG molecules/nm2. The mixture was allowed to react at room
temperature protected from light for 24 h. The PEGylated AuNPs were
centrifuged (4000 rpm, 20min) twice to remove excess of polymer and
re-dispersed in 1mL of PBS 1×.
4.3. Antibody labeling
Trastuzumab (Herceptin®, Genentech, South San Francisco, CA),
was labeled with AlexaFluor® 488 using Alexa Fluor® 488 Microscale
Protein Labeling Kit (A30006, Life Technologies, Thermo Fischer) ac-
cording to the provided protocol (Fig. S2C). Brieﬂy, 100 μg of
Trastuzumab in 100mM sodium bicarbonate buﬀer (pH 8.3) were in-
cubated with an appropriate volume of Alexa Fluor® 488 TFP ester
solution (11.3 nmol/μL), based on the desired dye:protein molar ratio
(55, 35, 25 and 15) for 15min. Unreacted dye was removed using a size
exclusion column provided in the kit. The degree of labeling (DOL) was
obtained via the concentration of protein measured by absorbance at
280 nm (A280) and the concentration of dye measured at an absor-
bance of 494 nm (A494) using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Rockland, Delaware, USA).
4.4. Antibody conjugation to AuNPs
The ﬁxed-orientation conjugation of Trastuzumab to PEG-coated
AuNPs was carried out as previously reported by Parolo et al. [43] with
slight modiﬁcations. A solution of 7.4 μL of N-Hydroxysulfosuccinimide
sodium salt (sulfo-NHS, Sigma-Aldrich) (100mg/mL) and 40 μL EDC
(10mg/mL) was prepared and mixed at room temperature for 10min.
This solution was then mixed with 1mg of PEGylated AuNPs and the
total volume was brought to 1mL with MES (Sigma-Aldrich) buﬀer
(10mM, pH 5). The suspension was incubated at 37 °C under shaking
(650 rpm) for 30min to activate the carboxylic groups of the PEG. After
the incubation, the conjugate solution was collected by centrifugation
(4000 rpm) for 5min and was mixed with 1 μg or 20 μg of TZB de-
pending on the desired number of TZB molecules per AuNPs (5 or 100
TZB, respectively). The solution was diluted to a ﬁnal volume of 1mL in
MES buﬀer. The supernatant containing the excess EDC-sulfo-NHS was
collected for quantiﬁcation of unbound TZB by the Bradford assay. The
diluted suspension of TZB-conjugated AuNPs was then incubated at
37 °C under shaking for 60min. The obtained conjugates were cen-
trifuged at 4000 rpm at 4 °C for 20min and then re-dispersed with 1mL
of sodium bicarbonate buﬀer (10mM, pH 8) at 37 °C for 30min under
shaking. The AuNPs were then centrifuged (4000 rpm) at 4 °C for
20min and the remaining activated carboxyl group was blocked with
40mM ethanolamine (Sigma-Aldrich) at pH 6. The resulting suspension
was then incubated at 37 °C under shaking (650 rpm) for 60min. Fi-
nally, the resulting oriented-TZB-conjugated AuNPs were centrifuged
(4000 rpm for 20min) and re-dispersed in 1mL PBS 1×.
4.5. Characterization methods
Optical characterization was carried out by UV–vis spectra of the
samples at 25 °C using a Jasco V-670 spectrophotometer (Jasco Europe
S.R.L., Milano, Italy), using 10mm path length quartz cuvettes. The
UV–vis spectra were acquired in water, PBS 1X, Dulbecco’s modiﬁed
Eagle medium (DMEM GlutaMAX™) cell culture medium supplemented
with 10% fetal calf serum (FCS), and FACS buﬀer to assess the colloidal
stability. The particle size was determined directly from UV–vis spectra
using the tabulated theoretical data of uncoated spherical AuNPs in
water described in Haiss et al. [15] Micrographs of the AuNPs were
taken with a Tecnai Spirit transmission electron microscope (FEI,
Frankfurt, Germany), operating at 120 kV. The images were recorded at
a resolution of 2048×2048 pixels (Veleta CCD camera, Olympus,
Volketswil, Switzerland). Fluorescence intensity was measured using a
ﬂuorescence plate reader with excitation wavelength centered at
485 nm and emission ﬁlter centered at 535 nm (Wallac 1420 VICTOR3
reader, PerkinElmer, Boston, MA), using appropriate band pass ﬁlters.
The surface charge of AuNP samples was measured in suspension of
50 μg/mL in PBS 1× at 25 °C using a phase amplitude light scattering
(PALS) zeta potential analyzer (Brookhaven Instruments Corporation,
Hotsville, NY, USA). The Smoluchowski approximation [59] was ﬁtted
to 10 cycles of electrophoretic mobility (EPM) measurements and 10
replicates were obtained for each sample to estimate the mean and
standard deviation (SD). Hydrodynamic size was measured by DDLS
(details about DDLS theory in SI). Samples were diluted into PBS 1×
and complete phenol red-free DMEM and measurements were carried
out at 25 °C with a scattering angle of 90°. DDLS spectra were collected
using a commercial goniometer instrument (LS instruments AG, Fri-
bourg, Switzerland) equipped with a 500mW diode pumped solid-state
laser (660 nm). Data was collected over 6min and three independent
correlation functions were measured. Further explanation of light
scattering measurements can be found in the supplementary informa-
tion.
The antibody conjugation yield was determined using the Bradford
protein concentration assay for both conjugation strategies [60]. After
conjugation, the AuNPs with TZB were centrifuged and the supernatant
was dialyzed against water to carry out the assay. A reference solution
was prepared having exactly the initial TZB concentration under the
same conditions. Therefore, the decrease in TZB concentration in the
supernatant can be directly correlated to the amount of antibody con-
jugated on the AuNPs. The AF488 amount on the AuNPs was
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determined by ﬂuorescence using a Perkin Elmer Victor Microplate
Reader (560/615 ﬁlter set). 10 μL of AuNPs samples were dissolved
with 10 μL of 40mM KCN (Sigma Aldrich) to avoid any interference
during the ﬂuorescence measurements.
4.6. Trastuzumab (TZB) binding activity by time-resolved depolarized
dynamic light scattering (DDLS)
DDLS measurements were performed to determine the ability of
TZB-conjugated AuNPs to recognize soluble ErbB2 receptor. Time-re-
solved DDLS, we were able to monitor changes in the hydrodynamic
radius of AuNPs when the TZB-ERBB2-ECD protein complex is formed.
In the DDLS experimental set-up, TZB-conjugated AuNPs and ERBB2-
ECD protein were free in solution at three TZB:ERBB2 ratios: 1:1
(1.10×1012 : 1.10× 1012), 1:2 (1.10× 1012 : 2.20×1012) and 1:5
(1.10×1012 : 5.50×1012). Time-resolved studies were carried out for
Au-PEG, Au-PEG-100TZB, and Au-PEG-100IgG at a gold concentration
of 0.15mM.
4.7. Enzyme-linked immunosorbent assay (ELISA)
The afﬁnity of AuNP-PEG-TZB for isolated ERBB2-ECD protein was
measured by direct ELISA assay as described in Troise et al. [37].
Brieﬂy a 96-well plate was coated with 62.6 nM of ERBB2-ECD protein,
at 0.358 μg protein per well in 100 μL miliQ water, kept overnight at
4 °C and blocked for 2 h at 25 °C with 1% Bovine Serum Albumin (BSA,
Sigma-Aldrich, Buchs, Switzerland). After blocking, the Au-PEG, Au-
PEG-100TZB and Au-PEG-IgG were incubated with a ratio 1:10 (AuNPs:
ERBB2-ECD). Binding was determined by measuring the absorption
from gold at 525 nm (corresponding to LSPR of AuNPs) using an ELISA
microplate spectrophotometer (ELISA Benchmark Plus, BIORAD, Seg-
rate, Italy).
4.8. Cell culture
Human breast cancer cell lines SK-BR-3, BT-474 (high ERBB2 ex-
pression), and MDA-MB-231 (low ERBB2 expression) were used in this
study [61]. Cells were cultured in DMEM supplemented with 10% FCS,
100 U/mL Penicillin and 100 μg/mL Streptomycin at 37 °C in 5% CO2.
All cell culture reagents were purchased from Life Technologies
(Thermo Fisher, Carlsbad, CA, USA).
4.9. Inductively coupled plasma optical emission spectroscopy
Cells were seeded at 2.5× 105 cells per well in 24-well plates. Cells
were allowed to adhere overnight, and the next day media was removed
and cells were exposed to AuNPs at concentration of 40 μg/mL. Cells
were incubated with NPs for 2 h and 24 h, and then washed twice with
PBS 1× . Cell-associated gold was measured by ICP-OES (Optima
7000DV, Perkin Elmer). Cells were treated with a 2:1 mixture of 65%
HNO3 (Sigma-Aldrich) and 30% H2O2 (Reacto Lab SA, Servion,
Switzerland) at 300 μL per sample and digested for 4 h. The samples
were brieﬂy sonicated at 50 °C prior to the addition of 400 μL of 37%
HCl (Sigma-Aldrich) and digested overnight. Finally, samples were
collected in 15mL tubes and diluted ten-fold with Milli-Q water. ICP-
OES measurements were performed at a wavelength of 242.795 nm
(limit of detection (LOD)=16 μg/L and limit of quantiﬁcation
(LOQ)= 23 μg/L), at an axial plasma view. The plasma ﬂow was
15mL/min and the sample ﬂow rate 1.5 mL/min. A washing-step was
performed between each measurement and each sample was measured
three times. Sample means were compared with a Split-plot ANOVA
with Huynh-Feldt correction for non-sphericity (p < 0.05) and
Bonferroni’s post hoc test.
4.10. Flow cytometry analysis
Cells were cultured overnight, harvested with trypsin 1× (Trypsin
10× diluted in PBS 1×; Sigma-Aldrich) and 2.5× 105 cells were
transferred to 5mL tubes. Cells were washed with FACS buﬀer (5 mM
ethylenediaminetetraacetic acid (EDTA), 3% FCS in PBS) by centrifu-
ging (1400 rpm at 4 °C for 5min) and re-suspending in 100 μL FACS
buﬀer containing 40 μg/mL of AuNPs. Incubation was done at room
temperature for 2 h, with gentle agitation. Untreated cells were used as
negative control while cells stained with 2 μg/mL of Trastuzumab and
20 μg/mL secondary antibody (Alexa Fluor 488 goat anti-human IgG,
Life Technologies) were used as positive control. Cells were then wa-
shed and re-suspended in 250 μL of FACS buﬀer. Each sample was ex-
amined in BD FACSCalibur and the sample measurements and data
analysis were performed with FlowJo Software (Ashland, OR, USA).
Each FACS analysis was repeated 6 times. Sample means were com-
pared with Krauskal-Wallis and U-Mann-Whitney non-parametric tests
(p < 0.05).
Associated content
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oriented conjugation; SDS-PAGE analysis of Trastuzumab and Au-PEG-
TZB samples; Colloidal stability of multifunctional AuNPs; Study of Au-
PEG-100TZB aﬃnity for ERBB2 receptor by ELISA and time-resolved
DDLS; Contrast phase images of SK-BR-3, BT-474 and MDA-MD-231;
MTT assay; ICP-OES of non-speciﬁc adsorption of AuNPs on well plate.
This material is available free of charge via the Internet.
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